Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/3/2025

Second-Line Treatment for Small Cell Lung Cancer

Introduction to Treatment Options

  • The American College of Chest Physicians recommends single-agent topotecan as the standard second-line treatment approach for patients with relapsed small cell lung cancer (SCLC), with an expected response rate of approximately 25% 1, 2

Treatment Selection Based on Relapse Timing

  • For patients with sensitive disease (relapse >3 months after first-line therapy), single-agent topotecan is the FDA-approved standard treatment with expected response rates of approximately 25% 2, 3
  • For patients who relapse >6 months after completion of initial chemotherapy, reinitiation of the previously administered first-line chemotherapy regimen is recommended 1, 4
  • For patients with refractory or resistant disease (relapse <3 months after first-line therapy), response rates to most agents are poor (≤10%), but topotecan remains an option 2, 5

Topotecan Administration

  • Oral topotecan (2.3 mg/m²/day for 5 days) is an equally effective alternative to IV administration with similar response rates, progression-free survival, and overall survival 1

Evidence Supporting Topotecan

  • A randomized phase III trial comparing single-agent IV topotecan with the combination regimen CAV (cyclophosphamide, doxorubicin, and vincristine) showed similar response rates (24% vs 18%), time to progression (13 weeks vs 12 weeks), and overall survival (25 weeks for both) 1, 3
  • Topotecan demonstrated better symptom control and slower decline in quality of life compared to best supportive care in patients with relapsed SCLC 1, 2
  • In a phase III trial, oral topotecan improved overall survival compared with best supportive care (26 vs. 14 weeks) 2, 6

Alternative Single-Agent Options

  • Other active single agents in the second-line setting include irinotecan, paclitaxel, docetaxel, vinorelbine, oral etoposide, and gemcitabine 1, 2
  • Amrubicin, an investigational anthracycline, has shown promising activity in phase II studies but is associated with significant neutropenia 2, 7

Treatment Duration and Monitoring

  • Subsequent chemotherapy should be given until 2 cycles beyond best response, progression of disease, or development of unacceptable toxicity 2, 6

Special Considerations

  • Performance status is an important factor in determining benefit from second-line therapy; patients with poor PS may not derive meaningful benefit 8, 9
  • Response rates are lower for patients with chemo-resistant or refractory disease compared with chemo-sensitive patients, regardless of performance status 8, 9

Common Pitfalls to Avoid

  • Avoid combination chemotherapy in the second-line setting as it increases toxicity without improving survival compared to single-agent therapy 1, 2